Scientific innovation and advances in ligand targeting have spurred the development of many different types of radiopharmaceutical (RPs) – radioisotopes bound to biological molecules to target specific organs, tissues, or cells within the body — with a wide range of clinical uses. As those uses have proliferated, and as research has continued to yield novel agents, developers and marketers of RP products are confronted with a regulatory environment that can be challenging to navigate, with health authorities struggling to keep up with the pace of innovation.
read this insight
By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Premier Research that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.